| Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model. | None |
| Modulation in vitro of H-ras oncogene expression by trans-splicing. | None |
| FTIR microscopic studies on normal and H-ras oncogene transfected cultured mouse fibroblasts. | None |
| The rasH2 mouse is a hemizygous transgenic mouse carrying the c-Ha-ras oncogene and that gene_s promoter/enhancer within the genetic background of a BALB/cByJ x C57BL/6F1 mouse. | None |
| Chromosomal rearrangements involving telomeric DNA sequences in Balb/3T3 cells transfected with the Ha-ras oncogene. | None |
| [Experimental study on the influence of Gynostemma pentaphyllam Mak upon point mutation of Ha-ras oncogene in blocking leukoplakia from canceration]. | None |
| Mammary carcinomas induced in human c-Ha-ras proto-oncogene transgenic rats are estrogen-independent, but responsive to d-limonene treatment. | None |
| initial cellular exposure to oncogenic Ras chronically activated the MAPK pathway in the cytoplasm, but transiently activated the same pathway in the nucleus | None |
| Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species | None |
| Simvastatin inhibits malignant transformation following expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. | None |
| Inhibitory effects of 17beta-estradiol and 4-n-octylphenol on 7,12-dimethylbenz[a]anthracene-induced mammary tumor development in human c-Ha-ras proto-oncogene transgenic rats. | None |
| Study of the 2719 mutant of the c-H-ras oncogene in a bi-intronic alternative splicing system. | None |
| Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival. | None |
| H-ras oncogene mutations during development of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced rat mammary gland cancer. | None |
| Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-ras. | None |
| rgr oncogene: activation by elimination of translational controls and mislocalization. | None |
| oncogenic H-ras promotes abnormal proliferation of CFU-E progenitors and early erythroblasts and supports their erythropoietin-independent growth | None |
| AciI and BstNI/CfrI detect all possible activating point mutations at codons 13 and 61 of the human H-ras oncogene. | None |
| CGG repeat polymorphism at the c-Ha-ras oncogene locus. | None |
| [Immortalization of cultured cells by the Ha-rasEJ oncogene and expression of a gene of biogenetic value]. | None |